Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

122.01 +1.71 (+1.42%)
Delayed Quote Updated: 3:07 PM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
News headline image
Incyte Maps Post-Jakafi Growth, Targeting Up to $4 Billion in Other Sales by 2030 ↗
Incyte (NASDAQ:INCY) is preparing for a transition away from its JAKAFI business, with Chief Executive Officer Bill Meury pointing to product launches and a pipeline of late-stage drug candidates as... 
Via MarketBeat
News headline image
1 healthcare stock to research further and 2 we avoid
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have... 
Via StockStory
News headline image
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Incyte (NASDAQ:INCY) Q3 Beat Overshadowed by Below-Consensus Sales Guidance ↗
Via Chartmill
Discover the top S&P500 movers in Monday's after-hours session. ↗
Via Chartmill
Incyte (NASDAQ:INCY) Combines High Growth Momentum With a Breakout Setup ↗
Via Chartmill
Incyte (NASDAQ:INCY) Combines Minervini Trend Template Strength With High-Growth Momentum ↗
Via Chartmill
News headline image
INCY Q3 deep dive: product diversification accelerates as R&D spending weighs on margins
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 14% year on yea... 
Via StockStory
S&P 500 Gap Movers for October 30, 2026 ↗
Via Chartmill
Topics Stocks
News headline image
Incyte (INCY) Q3 2026 Earnings Call Transcript ↗
Revenue grew 14% as core business surged 30%, with guidance raised on Opzelura momentum. 
Via The Motley Fool
Topics Earnings
News headline image
What Incyte (INCY) Said on Its Q3 Earnings Call ↗
Incyte (NASDAQ:INCY) reported third-quarter revenue of $1.56 billion, up 14% from a year earlier, as growth in its dermatology and hematology-oncology products helped offset a more modest increase in... 
Via MarketBeat
Topics Earnings
News headline image
Incyte’s (NASDAQ:INCY) Q3 2026 sales beat estimates but full-year sales guidance misses expectations significantly
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported revenue ahead of Wall Street’s expectations in Q3 2026, with revenue up 14% year on year ... 
Via StockStory
Topics Earnings
News headline image
Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates
From Incyte
Via Business Wire
News headline image
Incyte (INCY) reports Q3: everything you need to know ahead of earnings
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Thursday before market open. Here’s what to look for. Incyte beat a... 
Via StockStory
Topics Artificial Intelligence
News headline image
Incyte Highlights Promising Early Data for ’890 and ’734 in GI Cancers ↗
Incyte (NASDAQ:INCY) presented updated clinical data and development plans for two experimental solid-tumor programs at ESMO in Madrid: INCA33890, a TGFβR2-by-PD-1 bispecific antibody known as “’890,”... 
Via MarketBeat
News headline image
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026
From Incyte
Via Business Wire
News headline image
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
From Genmab A/S
Via Business Wire
News headline image
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
From Incyte
Via Business Wire
News headline image
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
From Incyte
Via Business Wire
News headline image
2 High-Flying Stocks with Competitive Advantages and 1 We Question
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo... 
Via StockStory
News headline image
Incyte to Report Third Quarter Financial Results
From Incyte
Via Business Wire
News headline image
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f... 
Via StockStory
Topics Artificial Intelligence
News headline image
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
From Mirum Pharmaceuticals, Inc. and Incyte
Via Business Wire
Discover the top S&P500 movers in Tuesday's pre-market session. ↗
Via Chartmill
News headline image
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio
From Incyte
Via Business Wire
News headline image
Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target ↗
Incyte (NASDAQ:INCY) executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after... 
Via MarketBeat
News headline image
3 Growth Stocks to Add to Your Roster
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil... 
Via StockStory
Topics Economy
News headline image
1 Cash-Heavy Stock for Long-Term Investors and 2 We Ignore
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o... 
Via StockStory
Topics Credit Cards
News headline image
Incyte (INCY): 3 Reasons We Love This Stock
Incyte’s 29% return over the past six months has outpaced the S&P 500 by 15.7%, and its stock price has climbed to $119.95 per share. This was partly thanks ... 
Via StockStory
Topics Artificial Intelligence Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS